scholarly journals P16‐121: Chronic eosinophilic pneumonia as a cause for progressive fibrotic lung diseases – A rare entity

Respirology ◽  
2021 ◽  
Vol 26 (S3) ◽  
pp. 501-502
2021 ◽  
Vol 14 (2) ◽  
pp. e234914
Author(s):  
Rishikesh Meena ◽  
Abhishek Goyal ◽  
Shashwat Kirti Keshri ◽  
Alkesh Kumar Khurana

Chronic eosinophilic pneumonia (CEP) is a rare disorder of unknown aetiology which comes under the class of diffuse parenchymal lung diseases with eosinophilia. It is classically characterised by blood and pulmonary eosinophilia, peripheral consolidation on chest radiograph and prompt response to corticosteroid therapy. We report a case of CEP in a 66-year-old man, smoker showing bilateral pulmonary infiltrates with mild peripheral eosinophilia. Our study shows that CEP can be kept as a possibility if radiological pictures are consistent, even if peripheral blood eosinophilia is mild.


Author(s):  
Tsarev S.V. Tsarev

Pulmonary eosinophilia is defined as infiltration of eosinophils into the lungs airways, interstitium, and alveoli. Various infections, drugs, parasites, autoimmune processes, malignancies and obstructive lung diseases have been associated with increased eosinophils in the lungs The eosinophilic pneumonias are a heterogeneous group of diseases characterized by an increase in eosinophils in lung tissue or bronchoalveolar lavage fluid. Many, but not all, of the eosinophilic pneumonias are also associated with a peripheral blood eosinophilia. The two main variants of the disease are acute and chronic eosinophilic pneumonia


1995 ◽  
Vol 32 (5) ◽  
pp. 733
Author(s):  
Hae Jeong Jeon ◽  
Jeong Hee Park ◽  
Jong Nam Lim ◽  
Tae Haeng Heo ◽  
Hyun Jun Shin

Respiration ◽  
2003 ◽  
Vol 70 (4) ◽  
pp. 362-366 ◽  
Author(s):  
Masayoshi Minakuchi ◽  
Akio Niimi ◽  
Hisako Matsumoto ◽  
Ryoichi Amitani ◽  
Michiaki Mishima

2021 ◽  
Vol 10 (11) ◽  
pp. 2285
Author(s):  
John N. Shumar ◽  
Abhimanyu Chandel ◽  
Christopher S. King

Progressive fibrosing interstitial lung disease (PF-ILD) describes a phenotypic subset of interstitial lung diseases characterized by progressive, intractable lung fibrosis. PF-ILD is separate from, but has radiographic, histopathologic, and clinical similarities to idiopathic pulmonary fibrosis. Two antifibrotic medications, nintedanib and pirfenidone, have been approved for use in patients with idiopathic pulmonary fibrosis. Recently completed randomized controlled trials have demonstrated the clinical efficacy of antifibrotic therapy in patients with PF-ILD. The validation of efficacy of antifibrotic therapy in PF-ILD has changed the treatment landscape for all of the fibrotic lung diseases, providing a new treatment pathway and opening the door for combined antifibrotic and immunosuppressant drug therapy to address both the fibrotic and inflammatory components of ILD characterized by mixed pathophysiologic pathways.


Cornea ◽  
2018 ◽  
Vol 37 (10) ◽  
pp. 1326-1327
Author(s):  
Takashi Nagamoto ◽  
Yoshinobu Mizuno ◽  
Chika Shigeyasu ◽  
Masaki Fukui ◽  
Masakazu Yamada

2007 ◽  
Vol &NA; ◽  
pp. S253
Author(s):  
Jan Plutinsky ◽  
Daniel Magula ◽  
Stefan Petricek ◽  
Dana Laukova ◽  
Stanislav Majernik ◽  
...  

CHEST Journal ◽  
1994 ◽  
Vol 106 (5) ◽  
pp. 1481-1486 ◽  
Author(s):  
Noriharu Shijubo ◽  
Katsunori Shigehara ◽  
Michio Hirasawa ◽  
Manabu Inuzuka ◽  
Shosaku Abe

Sign in / Sign up

Export Citation Format

Share Document